Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Dreger P, Ghia P, Schetelig J, Van Gelder M, Kimby E, Michallet M. et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood. 2018;132:892–902. https://doi.org/10.1182/blood-2018-01-826008.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912–20.

    Article  Google Scholar 

  3. 3.

    Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol. 2012;158:174–85.

    Article  Google Scholar 

  4. 4.

    Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27:362–9.

    CAS  Article  Google Scholar 

  5. 5.

    Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3 X trial. Blood. 2017;130:1477–80. https://doi.org/10.1182/blood-2017-04-775841.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Thompson PA, Stingo F, Keating MJ, Wierda WG, O’Brien SM, Estrov Z, et al. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017;177:567–77.

    CAS  Article  Google Scholar 

  7. 7.

    Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, et al. Risk factors for transplant failure after allogeneic stem cell transplantation of patients with CLL: a report from the European Society of Blood and Marrow Transplantation. Bone Marrow Transpl. 2017;52:552–60.

    CAS  Article  Google Scholar 

  8. 8.

    Helbig G, Spatec A, Wieczorkiewicz-Kabut A, Markiewicz M, Kopera M, Zelinska P, et al. Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience. Ann Hematol. 2019;98:1477–83. https://doi.org/10.1007/s00277-019-03679-x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008;22:1377–86.

    CAS  Article  Google Scholar 

  10. 10.

    Böttcher S, Ritgen M, Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev. 2011;25:91–6.

    Article  Google Scholar 

  11. 11.

    Thompson PA, Srivastava J, Peterson C, Strati P, Lorgenssen JL, Hether T, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134:1951–9.

    CAS  Article  Google Scholar 

  12. 12.

    Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017;30:2278–82.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to E. Montserrat.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rovira, M., Villamor, N., Cobo, F. et al. Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation. Bone Marrow Transplant 55, 1860–1861 (2020). https://doi.org/10.1038/s41409-020-0861-1

Download citation

Search